Zura Bio launches Phase 2 TibuSURE study of tibulizumab in systemic sclerosis

Zura Bio Ltd

TibuSURE is a global Phase 2 double-blind, placebo-controlled trial in ~80 adults with early diffuse cutaneous systemic sclerosis.
First clinical trial to target both BAFF and IL-17 pathways in SSC, using dual-antagonist antibody tibulizumab.
Primary endpoint is modified Rodnan Skin Score; key endpoints include lung function (qHRCT, FVC) and physical function (HAQ-DI, rCRISS).
Study includes 24-week efficacy period followed by a 28-week open-label extension.
First clinical site has been initiated; results expected to inform further development.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.